$157.47
3.562.31%
At close: -
$157.47
0.000.00%
After Hours: 7:15 PM EDT
Comments
Loading...
Latest Johnson & Johnson Stock News | NYSE:JNJ | Benzinga
Get the latest news on Johnson & Johnson stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Johnson & Johnson performance
Categories: All
Friday, April 18, 2025
Thursday, April 17, 2025
Wednesday, April 16, 2025
- Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
- Raymond James Maintains Outperform on Johnson...
- How Is The Market Feeling About Johnson & Johnson?
- Morgan Stanley Maintains Equal-Weight on John...
- RBC Capital Reiterates Outperform on Johnson ...
- Johnson & Johnson's Q1 Results, FY Guidance Highlight The 'Power Of The Pharma Portfolio'
Tuesday, April 15, 2025
- Johnson & Johnson Q1 Earnings: Strong Cancer Drug Sales, Boosts Quarterly Dividend, Anticipates Negative Currency Impact For 2025 Profit
- Genmab Announces Net Sales Of DARZALEX (darat...
- Johnson & Johnson Declared 4.8% Increase In T...
- Johnson & Johnson Expects 2025 Adjusted EPS O...
- Johnson & Johnson Expects 2025 Sales Of $91B-...
- Johnson & Johnson Q1 2025 Adj EPS $2.77 Beats...
- US Stock Futures Waver After Two-Day Rally: Trump's Tariff Moves Could End A 3-Year 'Rolling Recession,' Says Expert
- Citigroup, Bank Of America And 3 Stocks To Watch Heading Into Tuesday
- Earnings Scheduled For April 15, 2025
- Johnson & Johnson Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
- US Stock Futures Slip As Investors Brace Themselves For Netflix, AmEx Earnings This Week — Nikkei Up On Strong Sentiment
- 34-Year-Old Making $3,400 a Month in Dividends Shares His Top 7 Stocks — 'Be Lucky and Save Relentlessly'
Monday, April 14, 2025
Friday, April 11, 2025
Thursday, April 10, 2025
Wednesday, April 09, 2025
- This Johnson & Johnson Analyst Turns Bullish On Shifting Focus From Stelara Concerns To Innovative Medicine
- Morgan Stanley Maintains Equal-Weight on John...
- Amazon.com To $255? Here Are 10 Top Analyst Forecasts For Wednesday
- This Apple Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
- Goldman Sachs Upgrades Johnson & Johnson to B...
Tuesday, April 08, 2025
- Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst
- As Trump Tariffs Spark Panic, Investors Rush Into These 5 'Recession-Proof' ETFs
- Johnson & Johnson's New 'Compelling Data' Shows Sustained Symptom Improvement In Muscular Disease Patients
- Johnson & Johnson Presents New Data Showing L...
